Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Intravenous oncolytic vaccinia expressing transgenes for enhanced safety, inhibition of shedding, imaging, and systemic cancer immunotherapy.
Journal: Molecular therapy. Oncology
Published: August 21, 2025
Design and characterization of 4D-710, an aerosolized gene therapy for cystic fibrosis lung disease.
Design and characterization of 4D-710, an aerosolized gene therapy for cystic fibrosis lung disease.
Journal: American journal of respiratory cell and molecular biology
Published: April 10, 2025
Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies.
Journal: Investigative ophthalmology & visual science
Published: December 02, 2024
Viral Vector Technologies and Strategies: Improving on Nature.
Journal: International ophthalmology clinics
Published: July 01, 2021
Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing.
Journal: Molecular cancer therapeutics
Published: October 07, 2020
Quantification of RPE Changes in Choroideremia Using a Photoshop-Based Method.
Journal: Translational vision science & technology
Published: November 06, 2019
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).
Journal: Oncoimmunology
Published: November 27, 2018
A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: June 15, 2015
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: March 26, 2015
Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.
Journal: Current opinion in virology
Published: February 06, 2015
Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: January 21, 2015
Last Updated: 09/26/2026